Abstract | BACKGROUND: MATERIALS AND METHODS: RESULTS: Dose-response curves revealed a significant (P < 0.0001) decrease in human renal carcinoma cells with each 10-fold increase in concentration from 1 microm to 100 microm of five of these peptide hormones. There was an 81%, 74%, 66%, 70% and 70% elimination within 24 h in renal carcinoma cells secondary to vessel dilator, kaliuretic peptide, urodilatin, atrial natriuretic peptide and long-acting natriuretic peptide, respectively (P < 0.0001 for each), whereas BNP had no effect and CNP decreased renal cancer cell number by 10% (P = 0.04) at their 100 microm concentrations. Three days after treatment with these peptide hormones, the cancer cells began to proliferate again. The four cardiac hormones and urodilatin decreased DNA synthesis from 65-84% (P < 0.00001), whereas BNP and CNP decreased DNA synthesis 3% and 12% (both non-significant). Western blots revealed for the first time natriuretic peptide receptors (NPR)-A, -B and -C were present in the renal cancer cells. CONCLUSIONS:
|
Authors | B A Vesely, E J Eichelbaum, A A Alli, Y Sun, W R Gower Jr, D L Vesely |
Journal | European journal of clinical investigation
(Eur J Clin Invest)
Vol. 36
Issue 11
Pg. 810-9
(Nov 2006)
ISSN: 0014-2972 [Print] England |
PMID | 17032349
(Publication Type: Journal Article, Research Support, U.S. Gov't, Non-P.H.S.)
|
Chemical References |
- Antineoplastic Agents
- Peptide Fragments
- Natriuretic Peptide, Brain
- Ularitide
- Atrial Natriuretic Factor
- Receptors, Atrial Natriuretic Factor
|
Topics |
- Aged
- Antineoplastic Agents
(therapeutic use)
- Atrial Natriuretic Factor
- Carcinoma, Renal Cell
(drug therapy)
- Cell Proliferation
(drug effects)
- Humans
- Kidney Neoplasms
(drug therapy)
- Male
- Natriuretic Peptide, Brain
(therapeutic use)
- Peptide Fragments
- Receptors, Atrial Natriuretic Factor
(therapeutic use)
|